Compare · CNTX vs NVO
CNTX vs NVO
Side-by-side comparison of Context Therapeutics Inc. (CNTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 7859.2x CNTX ($22.1M).
- Over the past year, CNTX is down 83.1% and NVO is down 28.6% - NVO leads by 54.5 points.
- NVO has hit the wire 4 times in the past 4 weeks while CNTX has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 7 for CNTX).
- Company
- Context Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $0.24+1.75%
- $38.82-1.05%
- Market cap
- $22.1M
- $173.66B
- 1M return
- -36.04%
- -10.14%
- 1Y return
- -83.07%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 4
- Recent ratings
- 7
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CNTX
- Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
- Context Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
- SEC Form 10-Q filed by Context Therapeutics Inc.
- Context Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Amendment: SEC Form SCHEDULE 13G/A filed by Context Therapeutics Inc.
- Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
- SEC Form 4 filed by Director Pasternak Andy
- SEC Form 4 filed by Director Stacey Jennifer Evans
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank